Latest News
Data from 625 elderly Americans, followed for an average of 8.5 years, has revealed that those with very good or excellent vision at the beginning of the study had a 63% reduced risk of dementia over the study period.
A new test has been developed that measures amyloid-beta oligomers in the cerebrospinal fluid, promising a reliable means of early diagnosis.
An analysis technique using artificial neural networks has revealed that the most important factors for predicting whether amnestic mild cognitive impairment (MCI-A) would develop into Alzheimer’s within 2 years were hyperglycemia, female gender and having the APOE4 gene (in that order).
Data from over 900 community-dwelling older adults participating in the Rush Memory and Aging Project has found that greater purpose in life was associated with a substantially reduced risk of developing Alzheimer's disease, as well as a reduced risk of mild cognitive impairment and a slower rate
A brain scanning study using Pittsburgh Compound B, involving 42 healthy individuals (aged 50-80), of whom 14 had mothers who developed Alzheimer's, 14 had fathers with Alzheimer's, and 14 had no family history of the disease, has found that those with a maternal history had 15% more amyloid-beta
Midlife hypertension has been confirmed as a risk factor for the development of dementia in late life, but there have been conflicting findings about the role of late-life hypertension.
A study involving 57 cognitively healthy older adults has found that those who showed decreased memory performance two years later (20 of the 57) had higher baseline levels of phosphorylated tau231 in the cerebrospinal fluid, and more atrophy in the medial temporal lobe.
Rapamycin, a drug that keeps the immune system from attacking transplanted organs, was recently found to extend the life span of aged research mice.
Data from 330 participants in The 90+ Study, of whom 70% were women, has revealed an overall annual incidence rate of 18.2% for dementia, rising from 12.7% per year in the 90-94 age group, to 21.2% in the 95-99 age group and 40.7% per year in the 100+ age group.
A survey of more than 100 studies involving PIB-PET, a diagnostic tool that involves injecting a radiotracer called Pittsburgh compound B into the brain via the bloodstream, and imaging the brain with positron emission tomography (PET), has confirmed its sensitivity in detecting amyloid-beta prot